Correction (DOI:10.1016/j.jaad.2009.03.004);Tropical dermatology: Tropical diseases caused by protozoa

Journal of the American Academy of Dermatology

Volumn 60, Issue 6, 2009, Pages 897-925

  Lupi, Omar ^a   Bartlett, Brenda L ^f   Haugen, Reshma Nair ^b   Dy, Lady C ^b   Sethi, Aisha ^g   Klaus, Sidney N ^h   Machado Pinto, Jackson ^c   Bravo, Francisco ^d   Tyring, Stephen K ^e,f  

^a FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c Santa Casa de Belo Horizonte ^*  (Brazil)

^d INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^e University of Texas Health Science Center at Houston   (United States)

^f CENTER FOR CLINICAL STUDIES   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

amebiasis; Chagas disease; leishmaniasis; pneumocystosis; protozoa; toxoplasmosis; trypanosomiasis

Indexed keywords

ALBENDAZOLE; ALLOPURINOL; AMPHOTERICIN B; ANTIMONY DERIVATIVE; ATOVAQUONE; BENZNIDAZOLE; COTRIMOXAZOLE; DILOXANIDE; EFLORNITHINE; EMETINE; FLUCONAZOLE; IMIQUIMOD; ITRACONAZOLE; LEISHMANIA VACCINE; MEGLUMINE; MEGLUMINE ANTIMONATE; MELARSOPROL; METRONIDAZOLE; MILTEFOSINE; NIFURTIMOX; NITROFURAL; PAROMOMYCIN; PENTAMIDINE; PENTAMIDINE ISETHIONATE; PYRIMETHAMINE; RIFAMPICIN; SULFADIAZINE; SURAMIN; TINIDAZOLE; UNINDEXED DRUG;

ABDOMINAL PAIN; AFRICAN TRYPANOSOMIASIS; AMEBIASIS; ANEMIA; ANOREXIA; ARSENIC ENCEPHALOPATHY; ARTHRALGIA; BALAMUTHIA INFECTION; BALAMUTHIA MANDRILLARIS; BEHAVIOR CHANGE; BLOOD DYSCRASIA; BONE MARROW SUPPRESSION; BRAIN DISEASE; CARBON DIOXIDE LASER; CARDIOTOXICITY; CELLULAR IMMUNITY; CHAGAS DISEASE; CHORIORETINITIS; CLINICAL FEATURE; CLINICAL TRIAL; COLITIS; CONDYLOMA ACUMINATUM; CONGENITAL TOXOPLASMOSIS; CONJUNCTIVITIS; CRYOSURGERY; CRYOTHERAPY; CUTANEOUS PNEUMOCYSTOSIS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE TRANSMISSION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG MECHANISM; DRUG METABOLISM; DRUG WITHDRAWAL; EDEMA; ENTAMOEBA HISTOLYTICA; ERYTHEMA; EXFOLIATIVE DERMATITIS; GEOGRAPHIC DISTRIBUTION; HEART ARRHYTHMIA; HEART DISEASE; HEMOLYTIC ANEMIA; HUMAN; HYPERGLYCEMIA; HYPERTHERMIC THERAPY; HYPOGLYCEMIA; HYPOTENSION; IMMUNOCOMPROMISED PATIENT; IMMUNOTHERAPY; INJECTION SITE PAIN; INSOMNIA; KIDNEY FAILURE; LEISHMANIA; LEISHMANIASIS; LEISHMANIN SKIN TEST; LIVER AMEBIASIS; LOW DRUG DOSE; MORBIDITY; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OPTIC NERVE DISEASE; OPTIC NERVE INFLAMMATION; PAIN; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PNEUMOCYSTIS CARINII; PNEUMOCYSTOSIS; POLYNEUROPATHY; POTASSIUM DEPLETION; PRIORITY JOURNAL; PROTOZOAL INFECTION; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SIDE EFFECT; SKIN AMEBIASIS; SKIN BIOPSY; SKIN LEISHMANIASIS; SWEATING; TACHYCARDIA; TENDERNESS; TOXOPLASMA GONDII; TOXOPLASMOSIS; TROPICAL DISEASE; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI; VISCERAL LEISHMANIASIS; VOMITING; WEIGHT REDUCTION;

EID: 65649098712     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.09.032     Document Type: Erratum

References (199)

1. World Health Organization. Leishmaniasis. Available at: http://www.who.int/tdr/publications/publications/pdf/pr17/leishmaniasis.pdf. Accessed June 4, 2008.
2. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27 (2004) 305-318
3. Herwaldt B.L. Leishmaniasis. Lancet 354 (1999) 1191-1199
4. Mosleh I.M., Geith E., Natsheh L., Schönian G., Abotteen N., and Kharabsheh S. Efficacy of a weekly cryotherapy regimen to treat Leishmania major cutaneous leishmaniasis. J Am Acad Dermatol 58 (2008) 617-624
5. Korzeniewski K., and Olszański R. Leishmaniasis among soldiers of stabilization forces in Iraq. Review article. Int Marit Health 55 (2004) 155-163
6. Willard R.J., Jeffcoat A.M., Benson P.M., and Walsh D.S. Cutaneous leishmaniasis in soldiers from Fort Campbell, Kentucky returning from Operation Iraqi Freedom highlights diagnostic and therapeutic options. J Am Acad Dermatol 52 (2005) 977-987
7. Zapor M.J., and Moran K.A. Infectious diseases during wartime. Curr Opin Infect Dis 18 (2005) 395-399
8. Wright N.A., Davis L.E., Aftergut K.S., Parrish C.A., and Cockerell C.J. Cutaneous leishmaniasis in Texas: a northern spread of endemic areas. J Am Acad Dermatol 58 (2008) 650-652
9. Sangueza O.P., Lu D., Sangueza M., and Pereira C.P. Protozoa and worms. In: Bolognia J.L., Jorizzo J.L., and Rapini R.P. (Eds). Dermatology (2003), Mosby, London 1295-1307
10. Wirth D.F., Rogers W.O., Barker Jr. R., Dourado H., Suesebang L., and Albuquerque R. Leishmaniasis and malaria: new tools for epidemiologic analysis. Science 234 (1986) 975-979
11. Gramiccia M., and Grandoni L. The current status of zoonotic leishmaniases and approaches to disease control. Int J Parasitol 35 (2005) 1169-1180
12. Machado-Pinto J., and Azulay R.D. Leishmaniasis. In: Tyring S.K., Lupi O., and Hengge U.R. (Eds). Tropical dermatology (2006), Elsevier Inc, New York 41-48
13. Sousa-Franco J., Araújo-Mendes E., Silva Jardim I., L-Santos J., Faria D.R., Dutra W.O., et al. Infection-induced respiratory burst in BALB/c macrophages kills Leishmania guyanensis amastigotes through apoptosis: possible involvement in resistence to cutaneous leishmaniasis. Microbes Infect 8 (2006) 390-400
14. Ribeiro-Gomes F.L., Moniz-de-Souza M.C., Borges V.M., Nunes M.P., Mantuano-Barradas M., D'Avila H., et al. Turnover of neutrophils mediated by Fas ligand drives Leishmania major infection. J Infect Dis 192 (2005) 1127-1134
15. Eidismo L., Nylen S., Khamesipour A., Hedblad M.A., Chiodi F., and Akuffo H. The contribution of the Fas/FasL apoptotic pathway in ulcer formation during Leishmania major-induced cutaneous leishmaniasis. Am J Pathol 166 (2005) 1099-1108
16. Faria D.R., Gollob K.J., Barbosa Jr. J., Schriefer A., Machado P.R., Lessa H., et al. Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. Infect Immun 73 (2005) 7853-7859
17. Dowlati Y. Cutaneous leishmaniasis: clinical aspects. Clin Dermatol 14 (1996) 425-431
18. Silveira F.T., Lainson R., and Corbett C.E. Further observations on clinical, histopathological, and immunological features of borderline disseminated cutaneous leishmaniasis caused by Leishmania (leishmania) amazonensis. Mem Inst Oswaldo Cruz 100 (2005) 525-534
19. Furtado T.A.F. Leishmaniose tegumentar Americana. [in Portuguese]. In: Machado-Pinto J. (Ed). Doenças infecciosas com manifestações dermatológicas (1994), Editora Medsi, Rio de Janeiro, Brazil 319-328
20. Alvar J., Aparicio P., Aseffa A., Den Boer M., Cañavate C., Dedet J.P., et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21 (2008) 334-359
21. Pintado V., Martín-Rabadán P., Rivera M.L., Moreno S., and Bouza E. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 80 (2001) 54-73
22. Pasquau F., Ena J., Sanchez R., Cuadrado J.M., Amador C., Flores J., et al. Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region. Eur J Clin Microbiol Infect Dis 24 (2005) 411-418
23. Passos V.M.A., Barreto S.M., Romanha A.J., Krettli A.U., Volpini A.C., and Costa M.F.D.L. American cutaneous leishmaniasis: use of a skin test as a predictor of relapse after treatment. Bill WHO 78 (2000) 968-974
24. Rocha R.D., Gontijo C.M., Eloi-Santos S.M., Teixeira-Carvalho A., Correa-Oliveira R., Ferrari T.C., et al. Clinical value of anti-live Leishmania (Viannia) braziliensis immunoglobulin G subclasses detected by flow cytometry for diagnosing active localized cutaneous leishmaniasis. Trop Med Int Health 11 (2006) 156-166
25. Machado-Pinto J., Pinto J., Costa C.A., Genaro O., Marques M.J., Modabber F., et al. Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial. Int J Dermatol 41 (2002) 73-78
26. Spanakos G., Piperaki E.-T., Menounos P.G., Tegos N., Flemetakis A., and Vakalis N.C. Detection and species identification of Old World Leishmania in clinical samples using a PCR-based method. Trans R Soc Trop Med Hyg 102 (2008) 46-53
27. Berman J.D. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 24 (1997) 684-703
28. Al-Gindan Y., Kubba R., Omer A.H., and el-Hassan A.M. Cryosurgery in Old World cutaneous leishmaniasis. Br J Dermatol 118 (1988) 851-854
29. Ghosn S. Evaluation of sodium stibogluconate in the treatment of cutaneous leishmaniasis in Syria. Curr Med Res Opin 6 (1979) 280-283
30. Hepburn N.C. Cutaneous leishmaniasis: an overview. J Postgrad Med 49 (2003) 50-54
31. Asilian A., Sadeghinia A., Faghihi G., and Momeni A. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis. Ann Trop Med Parasitol 97 (2003) 493-498
32. Gurei M.S., Tatli N., Ozbilge H., Erel O., Seyrek A., Kocyigit A., et al. Efficacy of cryotherapy and intralesional pentostam in treatment of cutaneous leishmaniasis. J Egypt Soc Parasitol 30 (2000) 169-176
33. Wortmann G., Miller R.S., Oster C., Jackson J., and Aronson N. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis 35 (2002) 261-267
34. Olliaro P.L., Guerin P.J., Gerstl S., Haaskjold A.A., Rottingen J.A., and Sundar S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 5 (2005) 763-774
35. Alkhawajah A.M., Larbi E., al-Gindan Y., Abahussein A., and Jain S. Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration. Ann Trop Med Parasitol 91 (1997) 899-905
36. Herwaldt B.L., and Berman J.D. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentosam) and review of pertinent clinical studies. Am J Trop Med Hyg 46 (1992) 296-306
37. el-Safi S.H., Murphy A.G., Bryceson A.D., and Neal R.A. A double-blind clinical trial of the treatment of cutaneous leishmaniasis with paromomycin ointment. Trans R Soc Trop Med Hyg 84 (1990) 690-691
38. Asilian A., Jalayer T., Whitworth J.A., Ghasemi R.L., Nilforooshzadeh M., and Olliaro P. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg 53 (1995) 648-651
39. Faghihi G., and Tavakoli-kia R. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clin Exp Dermatol 28 (2003) 13-16
40. Asilian A., Jalayer T., Nilforooshzadeh M., Ghassemi R.L., Peto R., Wayling S., et al. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bull World Health Organ 81 (2003) 353-359
41. Murdaca G., Setti M., Campelli A., Ghio M., Puppo F., and Indiveri F. Liposomal amphotericin B for the treatment of acute phase and secondary prophylaxis of visceral leishmaniasis in a HIV positive patient. Infec Med 8 (2000) 241-244
42. Golenser J., and Domb A. New formulations and derivatives of amphotericin B for treatment of leishmaniasis. Mini Rev Med Chem 6 (2006) 153-162
43. Berman J. Miltefosine to treat leishmaniasis. Expert Opin Pharmacother 6 (2005) 1381-1388
44. Khatami A., Firooz A., Gorouhi F., and Dowlati Y. Treatment of Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol 57 (2007) 335 e1-29
45. Leibovici V., and Aram H. Cryotherapy in acute cutaneous leishmaniasis. Int J Dermatol 25 (1986) 473-475
46. Abramovits W., Losornio M., Marais G., and Perlmutter A. Cutaneous cryosurgery. Dermatol Nurs 18 (2006) 456-459
47. Thai K.-E., and Sinclair R.D. Cryosurgery of benign skin lesions. Aust J Dermatol 40 (1999) 175-178
48. Asilian A., Sadeghinia A., Faghihi G., and Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 42 (2004) 281-283
49. Panagiotopoulos A., Stavropoulos P.G., Hasapi V., Papakonstantinou A.M., Petridis A., and Katsambas A. Treatment of cutaneous leishmaniasis with cryosurgery. Int J Dermatol 44 (2005) 749-752
50. Nilforooshzadeh M.A., Jaffari F., and Malekafzali B. Efficacy of combined triple therapy (paramomycin ointment, cryotherapy, and intralesional Glucantime) in comparison with intrlesional Glucantime for the treatment of acute cutaneous leishmaniasis. [in Farsi]. Iran J Dermatol 7 (2004) 136-139
51. Reithinger R., Mohsen M., Wahid M., Bismullah M., Quinnell R.J., Davies C.R., et al. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis 40 (2005) 1148-1155
52. Lobo I.M., Soares M.B., Correia T.M., de Freitas L.A., Oliveira M.I., Nakatani M., et al. Heat therapy for cutaneous leishmaniasis elicits a systemic cytokine response similar to that of antimonial (Glucantime) therapy. Trans R Soc Trop Med Hyg 100 (2006) 642-649
53. Lessa H.A., Machado P., Lima F., Cruz A., Bacellar O., Guerreiro J., et al. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg 65 (2001) 87-89
54. Bacellar O., Lessa H., Schriefer A., Machado P., Ribeiro de Jesus A., Dutra W.O., et al. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun 70 (2002) 6734-6740
55. Slade H.B., Owens M.L., Tomai M.A., and Miller R.L. Imiquimod 5% cream (Aldara). Expert Opin Invest Drugs 7 (1998) 437-449
56. Miranda-Verastequi C., Llanos-Cuentas A., Arevalo I., Ward B.J., and Matlashewski G. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis 40 (2005) 1395-1403
57. De Paula C.D., Sampaio J.H., Cardoso D.R., and Sampaio R.N. A comparative study between the efficacy of pentamidine isothianate given in three doses for one week and N-Methyl-glucamine in a dose of 20 mgsbv/day for 20 days to treat cutaneous leishmaniasis. Rev Soc Bras Med Trop 36 (2003) 365-371
58. Yardley V., Croft S.L., DeDoncker S., Dujardin J.C., Koirala S., Rijal S., et al. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am Trop Med Hyg 73 (2005) 272-275
59. Mayrink W., Pinto J.A., Costa C.A., Toledo V., Guimaraes T., Genaro O., et al. Evaluation of the potency and stability of a candidate vaccine against American cutaneous leishmaniasis. Am J Trop Med Hyg 61 (1999) 294-295
60. Kenney R.T., Sacks D.L., Sypek J.P., Vilela L., Gam A.A., and Evans-Davis K. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 163 (1999) 4481-4488
61. Armijos R.X., Weigel M.M., Aviles H., Maldonado R., and Racines J. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety immunogenicity and eficaccy during the first 12 months of follow-up. J Infect Dis 177 (1998) 1352-1357
62. Sharifi I., Fekri A.R., Aflatonian M.R., Kamesipour A., Nadim A., Mousavi M.R., et al. Randomized vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 351 (1998) 1540-1543
63. Ivens A.C., Peacock C.S., Worthey E.A., Murphy L., Aggarwal G., Berriman M., et al. The genome of the kinetoplastid parasite, Leishmania major. Science 309 (2005) 436-442
64. Stauffer W., and Ravdin J.I. Entamoeba histolytica: an update. Curr Opin Infect Dis 16 (2003) 479-485
65. Parshad S., Grover P.S., Sharma A., Verma D.K., and Sharma A. Primary cutaneous amoebiasis: case report with review of the literature. Int J Dermatol 41 (2002) 676-680
66. Tanyuksel M., and Petri Jr. W.A. Laboratory diagnosis of amebiasis. Clin Microbiol Rev 16 (2003) 713-729
67. Sanchez-Guillen M.C., Pere-Fuentes R., Salgado-Rosas H., Ruiz-Argüelles A., Ackers J., Shire A., et al. Differentiation of Entamoeba histolytica/Entamoeba dispar by PCR and their correlation with humoral and cellular immunity in individuals with clinical variants of amebiasis. Am J Trop Med Hyg 66 (2002) 731-737
68. Magaña Garcia M., and Magaña M. Dermatología (2003), Editorial Panamericana, Mexico pp. 99-101
69. Rimzsa M.E., and Berg R.A. Cutaneous amebiasis. Pediatrics 71 (1983) 595-598
70. Magana M., Magana M.L., Alcantara A., and Perez-Martin M.A. Histopathology of cutaneous amebiasis. Am J Dermatopathol 26 (2004) 280-284
71. Al-Daraji W.I., Husain E.A., and Robson A. Primary cutaneous amebiasis with a fatal outcome. Am J Dermatopathol 30 (2008) 398-400
72. Braynstein H., and Conner D.H. Amebiasis-infection with Entamoeba histolytica. In: Connor D.H., Chandler F.W., Schwartz D.A., Manz H.J., Lack E.E., and Manz H. (Eds). Pathology of infectious diseases vol. II (1997), McGraw-Hill, New York
73. Li E., and Stanley S.L. Parasitic disease of the liver and intestines (amebiasis). Gastroenterol Clin 25 (1996) 471-489
74. Calderon J., Munoz M.L., and Acosta M.H. Surface redistribution and release of antibody-induced caps. Entamoeba J Exp Med 151 (1980) 184-193
75. Sra K.K., Sracic J., and Tyring S.K. Treatment of protozoan infections. Dermatol Ther 17 (2004) 513-516
76. Visvesvara G.S., Schuster F.L., and Martinez A.J. Balamuthia mandrillaris, N.G., N. Sp., agent of amebic meningoencephalitis in humans and other animals. J Eukaryot Microbiol 40 (1993) 504-514
77. Siddiqui R., and Khan N.A. Balamuthia amoebic encephalitis: an emerging disease with fatal consequences. Microb Pathog 44 (2008) 89-97
78. Magana M.L., Fernandez-Diez J., and Magana M. Cutaneous amebiasis in pediatrics. Arch Dermatol 144 (2008) 1369-1372
79. Schuster F.L., and Visvesvara G.S. Amebic encephalitides and amebic keratitis caused by pathogenic and opportunistic free-living amebas. Curr Treat Options Infect Dis 5 (2003) 273-282
80. Campos P., Cabrera J., Gotuzzo E., and Guillen D. Neurological involvement in free living amebiasis. Rev Neurol 29 (1999) 316-318
81. Recavarren-Arce S., Verlarde C., Gotuzzo E., and Cabrera J. Amoeba angeitic lesions of the central nervous system in Balamuthia mandrillaris amoebiasis. Hum Pathol 30 (1999) 269-273
82. Galarza C., Larrea P., and Kumakawa H. Amebiasis cutánea de vida libre. Primer caso reportado en el Hospital Dos de Mayo, Lima, Perú. Dermatología Peruana 7 (1997) 65-69
83. Ballona R., and Aquije M. Compromiso cutáneo en encefalitis granulomatosa amebiana fatal causada por Balamuthia mandrillaris Folia. Dermatología Peruana 14 (2003) 28-30
84. Taratuto A.L., Monges J., Acefe J.C., Meli F., Paredes A., and Martinez A.J. Leptomyxid amoeba encephalitis: report of the first case in Argentina. Trans R Soc Trop Med Hyg 85 (1991) 77
85. Galarza M., Cuccia V., Sosa F.P., and Monges J.A. Pediatric granulomatous cerebral amebiasis: a delayed diagnosis. Pediatr Neurol 26 (2002) 153-156
86. Martinez A.J., Guerra A.E., Garcia-Tamayo J., Cespedes G., Gonzalez-Alfonzo J.E., and Visvesvara G.S. Granulomatous amebic encephalitis: a review and report of a spontaneous case from Venezuela. Acta Neuropathol 87 (1994) 430-434
87. González-Alfonzo J.E., Martínez A.J., García V., García-Tamayo J., and Céspedes G. Granulomatous encephalitis due to a leptomyxid amoeba. Trans R Soc Trop Med Hyg 85 (1991) 480
88. Riestra-Castaneda J.M., Riestra-Castaneda R., Gonzalez-Garrido A.A., Pena Moreno P., Martinez A.J., Visvesvara G.S., et al. Granulomatous amebic encephalitis due to Balamuthia mandrillaris (Leptomyxiidae): report of four cases from Mexico. Am J Trop Med Hyg 56 (1997) 603-607
89. Chimelli L., Hahn M.D., Scaravilli F., Wallace S., and Visvesvara G.S. Granulomatous amoebic encephalitis due to leptomyxid amoebae: report of the first Brazilian case. Trans R Soc Trop Med Hyg 86 (1992) 635
90. Bakardjiev A., Azimi P.H., Ashouri N., Ascher D.P., Janner D., Schuster F.L., et al. Amebic encephalitis caused by Balamuthia mandrillaris: report of four cases. Pediatr Infect Dis J 22 (2003) 447-453
91. Pritzker A.S., Kim B.K., Agrawal D., Southern Jr. P.M., and Pandya A.G. Fatal granulomatous amebic encephalitis caused by Balamuthia mandrillaris presenting as a skin lesion. J Am Acad Dermatol 50 2 suppl (2004) 38-41
92. Sangruchi T., Martinez A.J., and Vivesvara G.S. Spontaneous granulomatous amebic encephalitis: report of four cases from Thailand. Southeast Asian J Trop Med Public Health 25 (1994) 309-313
93. Shirabe T., Monobe Y., and Visvesvara G.S. An autopsy case of amebic meningoencephalitis. The first Japanese case caused by Balamuthia mandrillaris. Neuropathology 22 (2002) 213-217
94. Reed R.P., Cooke-Yarborough C.M., Jaquiery A.L., Grimwood K., Kemp A.S., Su J.C., et al. Fatal granulomatous amoebic encephalitis caused by Balamuthia mandrillaris. Med J Aust 167 (1997) 82-84
95. Kodet R., Nohynkova E., Tichy M., Soukop J., and Visvesvara G.S. Amebic encephalitis caused by Balamuthia mandrillaris in a Czech child: description of the first case from Europe. Pathol Res Pract 194 (1998) 423-430
96. Denney C.F., Iragui V.J., Uber-Zak L.D., Karpinski N.C., Ziegler E.J., Visvesvara G.S., et al. Amebic meningoencephalitis caused by Balamuthia mandrillaris: case report and review. Clin Infect Dis 25 (1997) 1354-1358
97. Schuster F.L., Dunnebacke T.H., Booton G.C., Yagi S., Kohlmeier C.K., Glaser C., et al. Environmental isolation of Balamuthia mandrillaris associated with a case of amebic encephalitis. J Clin Microbiol 41 (2003) 3175-3180
98. Tavares M., Correia da Costa J.M., Carpenter S.S., Santos L.A., Afonso C., Aguiar A., et al. Diagnosis of first case of Balamuthia amoebic encephalitis in Portugal by immunofluorescence and PCR. J Clin Microbiol 44 (2006) 2660-2663
99. Schuster F.L., and Visvesvara G.S. Free-living amebae opportunistic and non-opportunistic pathogens of humans and animals. Int J Parasitol 34 (2004) 1001-1027
100. Schuster F.L., Glaser C., Honarmand S., Maguire J.H., and Visvesvara G.S. Balamuthia amebic encephalitis risk, Hispanic Americans. Emerg Infect Dis 10 (2004) 1510-1512
101. Siddiqui R., Ortega-Rivas A., and Khan N.A. Balamuthia mandrillaris resistance to hostile conditions. J Med Microbiol 57 (2008) 428-431
102. Visvesvara G.S., Martinez A.J., Schuster F.L., Leitch G.T., Wallace S.V., Sawyer T.K., et al. Leptomyxid ameba, a new agent of amebic meningoencephalitis in humans and animals. J Clin Microbiol 28 (1990) 2750-2756
103. Bravo F.G., Cabrera J., and Gotuzzo E. Cutaneous manifestations of infection by free living amebas, with special emphasis on Balamuthia mandrillaris. In: Tyring S.K., Lupi O., and Hengge U.R. (Eds). Tropical dermatology (2006), Elsevier, Philadelphia 49-56
104. Booton G.C., Carmichael J.R., Visvesvara G.S., Byers T.J., and Fuerst P.A. Genotyping of Balamuthia mandrillaris based on nuclear 18S and mitochondrial 16S rRNA genes. Am J Trop Med Hyg 68 (2003) 65-69
105. Schuster FL, Glaser C, Honarmand S, Visvesvara GS. Testing for Balamuthia amebic encephalitis by indirect immunofluorescence. In: Lares-Villa F, Booton GC, Marciano-Cabral F, editors. Proceedings of Xth International Meeting on the Biology and Pathogenicity of Free-Living Amebas, Ciudad Obregón, Mexico, October 5-10, 2003. pp. 173-8.
106. Martinez A.J., and Visvesvara G.S. Balamuthia mandrillaris infection. J Med Microbiol 50 (2001) 205-207
107. Booton G.C., Schuster F.L., Carmichael J.R., Fuerst P.A., and Byers T.J. Balamuthia mandrillaris: identification of clinical and environmental isolates using genus-specific PCR. J Eukaryot Microbiol 50 suppl (2003) 508-509
108. Schuster F.L., and Visvesvara G.S. Efficacy of novel antimicrobials against clinical isolates of opportunistic amebas. J Eukaryot Microbiol 45 (1998) 612-618
109. Deetz T.R., Sawyer M.H., Billman G., Schuster F.L., and Visvesvara G.S. Successful treatment of Balamuthia amoebic encephalitis: presentation of 2 cases. Clin Infect Dis 37 (2003) 1304-1312
110. Jung S., Schelper R.L., Visvesvara G.S., and Chang H.T. Balamuthia mandrillaris meningoencephalitis in an immunocompetent patient: an unusual clinical course and a favorable outcome. Arch Pathol Lab Med 128 (2004) 466-468
111. Semenovitch I., and Lupi O. Trypanosomiasis. In: Tyring S.K., Lupi O., and Hengge U.R. (Eds). Tropical dermatology (2006), Elsevier Inc, New York 29-39
112. Brun R., and Balmer O. New developments in human African trypanosomiasis. Curr Opin Infect Dis 19 (2006) 415-420
113. Sternberg J.M. Human African trypanosomiasis: clinical presentation and immune response. Parasit Immunol 26 (2004) 469-476
114. Goldsmith R.S. Infectious diseases: protozoal. Current medical diagnosis & treatment (2002), Appleton & Lange, Connecticut 1463-1465
115. Quinn T.C. African trypanosomiasis. In: Cecil R.L., Goldman L., and Bennett J.C. (Eds). Cecil textbook of medicine vol. 2 (1996), W.B. Saunders Company, Philadelphia 1896-1899
116. Rocha L.A.C., and Ferreira F.S.C. Tripanossomíase humana Africana. In: Veronesi R., and Ricardo V. (Eds). Tratado de infectologia vol. 2 (1996), Atheneu, São Paulo, Brazil 1306-1315
117. Bryceson A.D.M., and Hay R.J. Parasitic worms and protozoa. In: Rook A., Wilkinson D.S., Ebling F.J.G., and Champion R.H. (Eds). Rook/Wilkinson/Ebling textbook of dermatology. 6th ed. vol. 5 (1998), Blackwell Science Ltd, Oxford 1407-1408
118. Stich A., Barrett M.P., and Krishna S. Waking up to sleeping sickness. Trends Parasitol 19 (2003) 195-197
119. Waiswa C., Olaho-Mukani W., and Katunguka-Rwakishaya E. Domestic animals as reservoirs for sleeping sickness in three endemic foci in south-eastern Uganda. Ann Trop Med Parasitol 97 (2003) 149-155
120. Welburn S.C., and Odiit M. Recent developments in human African trypanosomiasis. Curr Opin Infect Dis 15 (2002) 477-484
121. McGovern T.W., Williams W., Fitzpatrick J.E., Cetron M.S., Hepburn B.C., and Gentry R.H. Cutaneous manifestations of African trypanosomiasis. Arch Dermatol 131 (1995) 1178-1182
122. Jamonneau V., Solano P., Garcia A., Lejon V., Djé N., Miezan T.W., et al. Stage determination and therapeutic decision in human African trypanosomiasis: value of polymerase chain reaction and immunoglobulin M quantification on the cerebrospinal fluid of sleeping sickness patients in Côte d'Ivoire. Trop Med Int Health 8 (2003) 589-594
123. Lejon V., Kwete J., and Büscher P. Towards saliva-based screening for sleeping sickness?. Trop Med Int Health 8 (2003) 585-588
124. Lejon V., Reiber H., Legros D., Djé N., Magnus E., Wouters I., et al. Intrathecal immune response pattern for improved diagnosis of central nervous system involvement in trypanosomiasis. J Infect Dis 187 (2003) 1475-1483
125. Bouteille B., Oukem O., and Bisser S. Treatment perspectives for human African trypanosomiasis. Fundam Clin Pharmacol 17 (2003) 171-181
126. Docampo R., and Moreno S.N. Current chemotherapy of human African trypanosomiasis. Parasitol Res 90 suppl 1 (2003) S10-S13
127. Nok A.J. Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis. Parasitol Res 90 (2003) 71-79
128. Burri C., and Brun R. Eflornithine for the treatment of human African trypanosomiasis. Parasitol Res 90 suppl 1 (2003) S49-S52
129. McGwire B.S., Olson C.L., Tack B.F., and Engman D.M. Killing of African trypanosomes by antimicrobial peptides. J Infect Dis 188 (2003) 146-152
130. Ferreira M.S., Lopes R.F., Chapadeiro E., et al. Doença de Chagas. In: Veronesi R., and Ricardo V. (Eds). Tratado de infectologia vol. 2 (1996), Atheneu, São Paulo, Brazil 1175-1213
131. Neva F.A. American trypanosomiasis (Chagas' disease). In: Cecil R.L., Goldman L., and Bennett J.C. (Eds). Cecil textbook of medicine vol. 2 (1996), W.B. Saunders Company, Philadelphia 1899-1903
132. Souza W. A short review on the morphology of Trypanosoma cruzi: from 1909 to 1999. Mem Inst Oswaldo Cruz 94 (1999) 17-36
133. Cetron M.S. Chagas disease. In: Jong E.C., and McMullen R. (Eds). The travel and tropical medicine handbook. 2nd ed. (1995), W.B. Saunders Company, Philadelphia 270-281
134. Rassi Jr. A., Rassi S.G., and Rassi A. Sudden death in Chagas disease. Arq Bras Cardiol 76 (2001) 75-96
135. Peters W., and Gilles H.M. Tropical medicine and parasitology. 4th ed. (1997), Mosby-Wolfe, London pp. 42-7
136. Dumonteil E., and Goubriere S. Predicting Triatoma dimidiate abundance and infection rate: a risk map for natural transmission of Chagas disease in the Yucatan peninsula of Mexico. Am J Trop Med Hyg 70 (2004) 514-519
137. Pung O.J., Banks C.W., Jones D.N., and Krissinger M.W. Trypanosoma cruzi in wild raccoons, opossums, and triatome bugs in Southeast Georgia, USA. Parasitol 81 (1995) 324-326
138. Yaeger R.G. The prevalence of T. cruzi infection in armadillos collected at a site near New Orleans, Louisiana. Am J Trop Med Hyg 38 (1998) 323-326
139. Yabsley M.J., and Noblet G.P. Seroprevalence of Trypanosoma cruzi in raccoons from South Carolina and Georgia. J Wildlife Dis 38 (2002) 75-83
140. Yabsley M.J., and Noblet G.P. Biological and molecular characterization of a raccoon isolate of Trypanosoma cruzi from South Carolina. J Parasitol 88 (2002) 1273-1276
141. Hancock K., Zajac A.M., Pung O.J., Elvinger F., Rosypal A.V., and Lindsay D.S. Prevalence of antibodies to Trypanosoma cruzi in raccoons (Procyon lotor) from an urban area of northern Virginia. J Parasitol 91 (2005) 470-472
142. Meurs K.M., Anthony M.A., Slater M., and Miller M.W. Chronic Trypanosoma cruzi infection in dogs: 11 cases (1987-1996). J Am Vet Assoc 213 (1998) 497-500
143. Bradley K.K., Bergman D.K., Woods J.P., Crutcher J.M., and Kirshhoff L.V. Prevalence of American trypanosomiasis (Chagas disease) among dogs in Oklahoma. J Am Vet Assoc 217 (2000) 1853-1857
144. Vaidian A.K., Weiss L.M., and Tanowitz H.B. Chagas disease and AIDS. Kinetoplastid Biol Dis 13 (2004) 1-6
145. Rivera J., Hillis L.D., and Levine B.D. Reactivation of cardiac Chagas disease in acquired immunodeficiency syndrome. Am J Cardiol 94 (2004) 1102-1103
146. Morel C.M. Chagas disease, from discovery to control-and beyond: history, myths and lessons to take home. Mem Inst Oswaldo Cruz 94 suppl 1 (1999) 3-16
147. Siqueira-Batista R., and Gomes A.P. Infections by Trypanosoma cruzi: revisiting Chagas disease. [in Portuguese]. J Bras Med 82 (2002) 28-41
148. Diaz J.H. Recognizing and reducing the risks of Chagas disease (American trypanosomiasis) in travelers. J Trav Med 15 (2008) 184-195
149. WHO Expert Committee on the Control of Chagas Disease. Contol of Chagas disease: second report of the WHO expert committee. Technical report series 905 (2003), World Health Organization, Geneva, Switzerland
150. Flores-Chavez M., Bosseno M.F., Bastrenta B., Dalenz J.L., Honetbeyrie M., Revollo S., et al. Polymerase chain reaction detection and serologic follow up after treatment with benznidazole in Bolivian children infected with a natural mixture of Trypanosoma cruzi I and II. Am J Trop Med Hyg 75 (2006) 497-501
151. Blanche C., Aleksic I., Takkenberg J.J., Czer L.S., Fishbein M.C., Trento A., et al. Heart transplantation for Chagas' cardiomyopathy. Ann Thorac Surg 60 (1995) 1406-1408
152. de Andrade A.L., Zicker F., de Oliveira R.M., Almeida Silva S., Luquetti A., Travassos L.R., et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348 (1996) 1407-1413
153. Apt W., Arribada A., Zulantay I., Solari A., Sánchez G., Mundaca K., et al. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the regression and prevention of electrocardiographic abnormalities during 9 years of follow-up. Ann Trop Med Parasitol 97 (2003) 23-29
154. Kroeger A., Villegas E., Ordoñez-González J., Pabon E., and Scorza J.V. Prevention of the transmission of Chagas' disease with pyrethroid-impregnated materials. Am J Trop Med Hyg 68 (2003) 307-311
155. Meireles L.R., Galisteo Jr. A.J., Pompeu E., and Andrade Jr. H.F. Toxoplasma gondii spreading in an urban area evaluated by seroprevalence in free-living cats and dogs. Trop Med Int Health 9 (2004) 876-881
156. Mawhorter S.D., Effron D., Blinkhorn R., and Spagnuolo P.J. Cutaneous manifestation of toxoplasmosis. Clin Infect Dis 14 (1992) 1084-1088
157. Montoya J.G., and Liesenfeld O. Toxoplasmosis. Lancet 363 (2004) 1965-1976
158. Jones J.L., Kruszon-Moran D., Wilson M., McQuillan G., Navin T., and McAuley J.B. Toxoplasma gondii infection in the United States: seroprevalence and risk factors. Am J Epidemiol 154 (2001) 357-365
159. Howe D.K., and Sibley D.L. Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease. J Infect Dis 172 (1995) 1561-1566
160. Ajzenberg D., Cogné N., Paris L., Bessières M.H., Thulliez P., Filisetti D., et al. Genotype of 86 Toxoplasma gondii isolates associated with human congenital toxoplasmosis and correlation with clinical findings. J Infect Dis 186 (2002) 684-689
161. Grigg M.E., Bonnefoy S., Hehl A.B., Suzuki Y., and Boothroyd J.C. Success and virulence in Toxoplasma as the result of sexual combination between two distinct ancestries. Science 294 (2001) 161-165
162. Sibley L. Recent origins among ancient parasites. Vet Parasitol 115 (2003) 185-198
163. Many A., and Koren G. Toxoplasmosis during pregnancy. Can Fam Physician 52 (2006) 29-30
164. Porter S.B., and Sande M. Toxoplasmosis of the central nervous sustem in the acquired immunodeficiency syndrome. N Engl J Med 327 (1992) 1643-1648
165. Lum F., Jones J.L., Holland G.N., and Liesegang T.J. Survey of ophthalmologists about ocular toxoplasmosis. Am J Ophthalmol 140 (2005) 724-726
166. Montoya J.G., and Remington J.S. Toxoplasmic chroriretinitis in the setting of acute acquired toxoplasmosis. Clin Infect Dis 23 (1996) 277-282
167. Holland G.N. Reconsidering the pathogenesis of ocular toxoplasmosis. Am J Ophthalmol 128 (1999) 502-505
168. Delaporte E., Alfandari S., Piette F., and Fortier B. Cutaneous manifestations of toxoplasmosis. Int J Dermatol 34 (1995) 443
169. Fernandez D.F., Wolff A.H., and Bagley M.P. Acute cutaneous toxoplasmosis presenting as erythroderma. Int J Dermatol 33 (1994) 129-130
170. Solovastru L., and Amalinei C. Morphea associated with toxoplasmosis. Rev Med Chir Soc Med Nat Iasi 107 (2003) 646-649
171. Saberin A., Lutgen C., Humbel R.L., and Hentges F. Dermatomyositis-like syndrome following acute toxoplasmosis. Bull Soc Sci Med Grand Duche Luxemb 2 (2004) 109-119
172. Kawakami Y., Hayashi J., Fujisaki T., Tani Y., Kashiwagi S., and Yamaga S. A case of toxoplasmosis with dermatomyositis. Kansenshogaku Zasshi 69 (1995) 1312-1315
173. Eymard B. Polymyositis, dermatomyositis and inclusion body myositis, nosological aspects. Presse Med 32 (2003) 1656-1667
174. Portegies P., Solod L., Cinque P., Chaudhuri A., Begovac J., Everall I., et al. Guidelines for the diagnosis and management of neurological complications of HIVinfection. Eur J Neurol 11 (2004) 297-304
175. Masur H., Kaplan J.E., and Holmes K.K. U.S. Public Health Service; Infectious Diseases Society of America. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 137 5 pt 2 (2002) 435-478
176. Walter P.D. Pneumocystis carinii: a historical perspective. Semin Respir Infect 13 (1998) 279-282
177. Thomas C.F., and Limper A.H. Pneumocystis pneumonia: clinical prevention and diagnosis in patients with and without immune deficiency syndrome. Semin Respir Infect 13 (1998) 289-295
178. Bellamy R. Pneumocystis pneumonia in people with HIV. Clin Evid 13 (2005) 854-868
179. Bundow D.L., and Aboulafia D.M. Skin involvement with Pneumocystis despite dapsone prophylaxis: a rare cause of skin nodules in a patient with AIDS. Am J Med Sci 13 (1997) 182-186
180. Stringer J.R., Beard C.B., Miller R.F., and Wakefield A.E. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 8 (2002) 891-896
181. Agarwal R., Reddy C., Aggarwal A.N., and Saxena A.K. It's Pneumocystis jiroveci not Pneumocystis carinii. Chest 129 (2006) 498
182. Tsai H.C., Lee S.S., Lin H.H., Lu L.Y., and Liu Y.C. Pneumocystis carinii pneumonia in systemic lupus erythematosus: a report of two cases. J Formos Med Assoc 100 (2001) 699-702
183. Lee A. Neonatal lupus: clinical features and management. Pediatr Drugs 6 (2004) 71-78
184. McKeon D.J., White W., Sinclair D., and Goldman J.M. Pneumocystis carinii pneumonia infection in a patient with known chronic mucocutaneous candidiasis. Respirology 10 (2005) 399-401
185. Ullmer E., Mayr M., Binet I., Ebnother-Staub C., Dalquen P., Soler M., et al. Granulomatous Pneumocystis carinii pneumonia in Wegener's granulomatosis. Eur Respir J 15 (2000) 213-216
186. Worth L.J., Dooley M.J., Seymour J.F., Mileshkin L., Slavin M.A., and Thursky K.A. An analysis of the utilization of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. Br J Cancer 92 (2005) 867-872
187. Barbier C., Arnaout L., Schmit C., Aucouturier J.S., Ricome J.L., and Loubieres Y. Respiratory failure due to Pneumocystis carinii following methotrexate therapy for gestational trophoblastic disease. BJOG 112 (2005) 382-383
188. Ng V.L., Yajko D.M., and Hadley W.K. Extrapulmonary pneumocystosis. Clin Microbiol Rev 10 (1997) 401-418
189. Al Soub H., Taha R.Y., El Deeb Y., Almaslamani M., and Al Khuwaiter J.Y. Pneumocystis carinii pneumonia in a patient without a predisposing illness: case report and review. Scand J Infect Dis 36 (2004) 618-621
190. Palazzi D.L., and Edwards M.S. Pneumocystis carinii pneumonia in a previously healthy infant. Semin Pediatr Infect Dis 13 (2002) 300-302
191. de Souza W., and Benchimol M. Basic biology of Pneumocystis carinii: a mini review. Mem Inst Oswaldo Cruz 100 (2005) 903-908
192. Swain S.D., Meissner N.N., and Harmsen A.G. CD8 T cells modulate CD4 T-cell and eosinophil-mediated pulmonary pathology in pneumocystis pneumonia in B-cell-deficient mice. Am J Pathol 168 (2006) 466-475
193. Peterson J.C., and Cushion M.T. Pneumocystis: not just pneumonia. Curr Opin Microbiol 8 (2005) 393-398
194. Katz M.N., Hessol N.A., Buchbinder S.P., Hirozawa A., O'Malley P., and Holmberg S.D. Temporal trends of opportunistic infections and malignancies in homosexual men with AIDS. J Infect Dis 170 (1994) 198-202
195. Wozniacka A., Robak E., Sysa-Jedrzejowska A., and McCauliffe D.P. Pneumocystis carinii mimicking neonatal lupus erythematosus-related pneumonitis. Pediatr Dermatol 20 (2003) 524-528
196. Coulman C.U., Greene I., and Archibald W.R. Cutaneous pneumocystosis. Ann Intern Med 106 (1987) 396-398
197. Cregan P., Yamamoto A., Lum A., VanderHeide T., MacDonald M., and Pulliam L. Comparison of four methods for rapid detection of Pneumocystis carinii in respiratory specimens. J Clin Microbiol 28 (1990) 2432-2436
198. Castro M. Treatment and prophylaxis of Pneumocystis carinii pneumonia. Semin Respir Infect 13 (1998) 296-303
199. Centers for Disease Control and Prevention. Laboratory Identification of Parasites of Public Health Concern. Available at: http://www.dpd.cdc.gov/dpdx/HTML/Pneumocystis.htm. Accessed June 30, 2008.